Please assess the completion status of the following clinical trial:

Trial Title: Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 to 80.~2. Confirmed COVID-19 diagnosis(including the clinically confirmed cases in Hubei).~3. Accord with any of the following: respiratory distress, RR ≥ 30 breaths/min; or SpO2 ≤ 93% at rest; or partial arterial oxygen pressure (PaO2) / fraction of inspiration O2 (FiO2) \>100mmHg and ≤ 300mmHg (1mmHg = 0.133kPa).~4. Chest imaging confirms lung involvement and has inflammatory exudation or pleural effusion.~Exclusion Criteria:~1. Cannot obtain informed consent.~2. Severe hepatic dysfunction (Child Pugh score ≥ C, or AST\> 5 times the upper limit); Severe renal dysfunction (estimated glomerular filtration rate ≤ 30mL / min / 1.73 m2) or receive continuous renal replacement therapy, hemodialysis, or peritoneal dialysis.~3. Unsatisfactory controlled hypertension (seated systolic blood pressure\> 160mmHg, or diastolic blood pressure\> 100mmHg); previous history of hypertension crisis or hypertensive encephalopathy.~4. Poorly controlled heart diseases, such as NYHA class II and above cardiac insufficiency, unstable angina pectoris, myocardial infarction within 1 year before enrollment, supraventricular or ventricular arrhythmia need treatment or intervention.~5. Hereditary bleeding tendency or coagulopathy; received full-dose anticoagulant or thrombolytic therapy within10 days before enrollment, or have taken non-steroidal anti-inflammatory drugs with platelet suppression within 10 days before enrollment (Except those who use small doses of aspirin ≤325mg / day for preventive use).~6. Thrombosis within 6 months before enrollment. And from those patients, screen who had arterial / venous thromboembolic events, such as, ischemic stroke, transient ischemic attack, deep venous thrombosis, pulmonary embolism, etc. within 1 year ahead of enrollment. Severe vascular disease (including aneurysms or arterial thrombosis requiring surgery) within 6 months before enrollment.~7. Unhealed wounds, active gastric ulcers or fractures. Gastrointestinal perforation, gastrointestinal fistula, abdominal abscess, visceral fistula formation within 6 months before enrollment. Major surgery (including preoperative Chest biopsy) or major trauma (such as a fracture) within 28 days before enrollment. May have surgery during the trial.~8. Severe, active bleeding such as hemoptysis, gastrointestinal bleeding, central nervous system bleeding, and nosebleeds within 1 month before enrollment.~9. Malignant tumors within 5 years before enrollment.~10. Allergic to bevacizumab or its components.~11. Untreated active hepatitis or HIV-positive patients.~12. Pregnant and lactating women and those planning to get pregnant.~13. Participated in other clinical trials, not considered suitable for this study by the researchers.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- bevacizumab plus standard care (Type: EXPERIMENTAL): Under ECG monitoring, give bevacizumab 500mg + 0.9% sodium chloride solution 100ml via intravenous drip, time is no less than 90min.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete